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We have shown that a bacteriophage lambda genetic screen system may be useful in predicting the activity and phenotype
of HIV-1 protease in the course of viral infection and antiretroviral therapy. This simple and rapid genetic screening system
has been used here to characterize HIV-1 proteases encoding single primary resistance substitutions. Except for proteases
with amino acid changes at positions 46 and 84, proteases containing single-resistance substitutions displayed a lower
catalytic efficiency than the WT enzyme. Single mutants could be identified by their efficiency, demonstrating that modest
differences in protease activity can be monitored with this simple assay. Overall, drug susceptibility could be reduced by
introduction of single mutations. However, high-level protease inhibitor (PI) resistance was only achieved by multiple mutated
proteases. The small but reproducible increase in resistance displayed by single mutants also demonstrated the ability of this
genetic screen system for detecting minor reductions in drug susceptibility. These results show that the bacteriophage
lambda genetic screen system used here is a useful tool in the analysis of specific contribution of mutations in the HIVINTRODUCTION
Protease inhibitors (PI) are extensively used in combi-
nation with reverse transcriptase inhibitors in the treat-
ment of human immunodeficiency virus type 1 (HIV-1)
infected patients (Carpenter et al., 2000). The clinical use
of combination regimens (including at least three anti-
retroviral drugs) has reduced HIV-1-related morbidity and
mortality (Palella et al., 1998). However, when therapies
fail to achieve a complete and sustained suppression of
virus replication, drug-resistant virus mutants can
emerge (Hirsch et al., 2000). PI resistance appears to be
the consequence of a multifactorial process, which in-
cludes protease gene mutations as well as changes
outside of its DNA-coding region (Bally et al., 2000; Cote
et al., 2001; Doyon et al., 1996; Kaufmann et al., 2001;
Koch et al., 2001; La Seta Catamancio et al., 2001; Mam-
mano et al., 1998; Shafer et al., 1999; Zennou et al., 1998;
Zhang et al., 1997). A progressive accumulation of muta-
tions in the protease-coding region has been observed
either in HIV-1 protease derived from treated patients or
in tissue-culture replication studies (Cabana et al., 1999;
Carrillo et al., 1998; Condra et al., 1995; Hertogs et al.,
2000; Kaufmann et al., 2001; Mammano et al., 1998; Molla
et al., 1996; Shafer et al., 1998; Vaillancourt et al., 1999;
Zhang et al., 1997). In both cases, a complex mutational
pattern has been observed. Amino acid changes in the71protease-coding region categorized as primary resis-
tance mutations basically affect enzyme susceptibility to
drug binding (Maschera et al., 1996; Schock et al., 1996).
Primary resistance substitutions are the first to appear
and are considered to be critical for drug resistance.
Secondary resistance substitutions also contribute to
overall drug resistance but they may have less direct
effect on inhibitor binding. Secondary mutations develop
later and improve enzyme function (Boden and Marko-
witz, 1998; Hirsch et al., 2000; Mammano et al., 2000).
Although cross-resistance can be detected among the
current PIs, every PI seems to be associated with certain
primary resistance mutations. Amino acid substitutions
V82A and I84V emerged in patients treated with ritonavir
(RTV) and after several ex vivo serial passages of HIV-1
laboratory-adapted strains (Boden and Markowitz, 1998;
Eastman et al., 1998; Markowitz et al., 1995; Molla et al.,
1996; Schmit et al., 1996). Saquinavir (SQV) predomi-
nantly selects the amino acid changes L90M and G48V
that are accompanied by other mutations (Boden and
Markowitz, 1998; Craig et al., 1998; Ives et al., 1997;
Jacobsen et al., 1996; Roberts, 1995; Vaillancourt et al.,
1999). For indinavir (IDV) primary substitutions M46L and
V82A may not be the first mutations, but they are se-
lected in most patient isolates in combination with other
mutations (Boden and Markowitz, 1998; Condra et al.,
1995, 1996; Zhang et al., 1997). Ex vivo serial passages of
HIV-1 in the presence of nelfinavir (NFV) resulted inprotease-coding region or in specific cleavage sites that a
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lected in patients treated with NFV-containing regimens
(Atkinson et al., 2000; Boden and Markowitz, 1998; Patick
et al., 1996, 1998). Finally, amprenavir-containing treat-
ments have been recently shown to select the substitu-
tion I50V, which has not been previously reported with
other PIs (Boden and Markowitz, 1998). It seems that
there are signature mutations for the specific PI resis-
tance. However, common mutations that confer cross-
resistance can also be selected. Thus, NFV can select
the substitution L90M in addition to D30N and amprena-
vir can select the substitution I84V in addition to I50V
(Hirsch et al., 2000).
Recently, we have adapted a new genetic assay sys-
tem (Sices and Kristie, 1998), based on the bacterio-
phage lambda, for the characterization of the activity and
phenotype of HIV-1 proteases (Martinez et al., 2000). This
genetic screen system is based on the bacteriophage
lambda regulatory circuit where the viral repressor cI is
specifically cleaved to initiate lysogenic to lytic switch.
Introduction of an HIV-1 protease in a wild-type (WT)
phage will cleavage a mutant cI repressor containing a
specific HIV-1 protease cleavage site, allowing the
phage to go into the lytic replication cycle. Here, we
report the characterization of the activity of seven HIV-1
single mutant proteases encoding one primary resis-
tance mutation: D30N, M46L, G48V, I50V, V82A, I84V, or
L90M. We also assessed how these substitutions affect
PI susceptibility. This genetic screen system provides a
simple alternative approach to the evaluation of the cat-
alytic activity and phenotype of HIV-1 protease variants.
RESULTS
Influence of primary resistance mutations on HIV-1
protease activity
We previously showed that the catalytic activity of
HIV-1 protease can be monitored by using a simple
bacteriophage-based genetic screen system (Martinez
et al., 2000). Specific cleavage of the HIV-1 p17/p24
(SQNYPIVQ) cleavage site located inside cI lambda re-
pressor allowed the characterization of the HIV-1 pro-
tease catalytic activity (Martinez et al., 2000; Sices and
Kristie, 1998). Several studies have demonstrated that
viral variants encoding multiple PI resistance mutations
show a variable reduction in drug-free virus infectivity
(Bleiber et al., 2001; Mammano et al., 1998, 2000; Mar-
tinez-Picado et al., 1999, 2000; Nijhuis et al., 1999; Stod-
dart et al., 2001; Zennou et al., 1998). In the present study
we established the impact of single primary resistance
substitutions in the catalytic efficiency of HIV-1 protease
by using the abovementioned genetic screen system.
Phages containing the HIV-1 protease single mutants
D30N, M46L, G48V, I50V, V82A, I84V, and L90M were
constructed (-HIVp). Escherichia coli cells expressing
the HIV-1 cI repressor construct were then infected with
recombinant phages encoding the different mutant pro-
tease enzymes. After two cycles of selective growth (see
Materials and Methods), the resulting phage was titered
(Fig. 1). A phage encoding the protease from the labora-
tory strain HXB2 (-HIVpHXB2) was used as positive
control and designated as the catalytic activity of WT
HIV-1 protease. Similarly, a phage encoding an inverted
HXB2 protease (-HIVpinvHXB2) was used as negative
control. As shown in Fig. 1, recombinant phages encod-
ing single mutant proteases displayed growth efficiency
that ranges from 0.05- to 0.95-fold of the WT -HIVpHXB2
growth. Importantly, the presence of different point mu-
tations resulted in different degrees of protease activity.
Phages encoding the amino acid substitutions M46L and
I84V were the only single-mutant protease phages that
replicated similarly to the WT -HIVpHXB2 phage. Ac-
cordingly, the growth titers for -HIVpM46L and
-HIVpI84V (2900 700 and 2700 700 PFU/l, respec-
tively) were not statistically different (P  0.63 and P 
0.26, respectively) from that obtained with the WT
-HIVpHXB2 (3000  1100 PFU/l). The phage encoding
the amino acid substitutions D30N replicated up to 20
times less efficiently than the WT -HIVpHXB2 phage,
displaying the lowest growth efficiency (150  80 PFU/
l) of all single mutants analyzed in this study. Phages
encoding the amino acid substitutions G48V, I50V, or
L90M were also less efficient than WT -HIVpHXB2
phage, showing growth titers of 1300  600, 1100  300,
and 1100  500 PFU/l, respectively. Nevertheless, the
catalytic efficiency of the G48V, I50V, and L90M single
mutants were much higher (8-fold) than that observed
with the phage encoding the D30N substitution (P 
0.001), but lower (0.4-fold) than that observed with the
WT HIV-1 protease (P  0.001). The phage encoding
the amino acid substitution V82A replicated more effi-
FIG. 1. Comparative growth of phages containing the HIV-1 protease
single mutants in cells expressing the cI.HIV-1-cro construct. The
growth of phages encoding a single protease substitution (gray bars)
was compared to the growth of WT -HIVpHXB2 (black bar). The growth
of a phage encoding an inverted HXB2 protease -HIVpinvHXB2 is also
included (white bar). Average values and standard deviation are illus-
trated. Each data point is the average of 13 to 38 independent exper-
iments, depending on specific phage.
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ciently than -HIVpD30N, but less efficiently than
-HIVpG48V, -HIVpI50V, or -HIVpL90M (Fig. 1). Thus,
-HIVpV82A growth titer (600  300 PFU/l) was statis-
tically different from that obtained with phages encoding
the substitutions G48V, I50V, or L90M (P  0.001). In
brief, we have found that the seven single mutant pro-
teases tested could be grouped in four different levels of
catalytic activity. These findings demonstrate that quan-
titation of the protease activity with the bacteriophage
lambda-based genetic screen system makes it possible
to monitor a wide range of different proteolytic activities.
Furthermore, as -HIVpD30N is a catalytically compro-
mised mutant, the system is sensitive enough to charac-
terize proteases of low catalytic activity.
Effect of single substitutions on resistance to PIs
Seven point substitutions have been designated as
primary resistance mutation due to its critical role in
conferring drug resistance. The bacteriophage lambda-
based genetic screen system was used to assess how
the different primary resistance substitutions affect the
HIV-1 protease susceptibility to four different PIs: IDV,
RTV, SQV, and NFV. For every recombinant phage we
evaluated the growth efficiency in the presence of vary-
ing concentrations of each PI and calculated the IC50
against each mutant (see Table 2 and Fig. 2). We com-
pared these values with those obtained with the phage
encoding the WT HIV-1 protease (-HIVpHXB2). None of
the single mutant phages displayed a high level of drug
resistance. The phage encoding the I84V substitution
showed the highest and widest level of resistance, being
10-fold more resistant to IDV than WT -HIVpHXB2 and
cross-resistant to SQV (9-fold) and RTV (8-fold) (Fig. 2).
The phage encoding the substitution G48V was clearly
less sensitive to SQV (sevenfold) and IDV (fourfold) than
WT -HIVpHXB2, but not to RTV and NFV. The mutant
M46L displayed a greater resistance to RTV (fivefold) and
IDV (threefold) than WT -HIVpHXB2. In contrast, the
phage encoding the substitution D30N was only slightly
more resistant to NFV (threefold) than WT -HIVpHXB2.
Interestingly, this phage encoding the substitution D30N
appeared to be more susceptible to RTV (15-fold) than
WT -HIVpHXB2 (Fig. 2B). Resistance to amprenavir is
characterized by the appearance of the I50V substitution.
As expected, the phage encoding the substitution I50V
did not display a significant increase in resistance to
SQV, RTV, IDV, and NFV. Substitution at position 82, which
is primarily associated with IDV and RTV resistance,
showed a decrease of susceptibility (seven- and three-
fold, respectively) to both drugs. Finally, the phage en-
FIG. 2. PI resistance and sensitivity of phages containing the HIV-1 protease single mutants (-HIVps) (gray bars). Resistance or sensitivity to PIs
was calculated for each mutant on the basis of IC50 values (Table 2) as fold increase or decrease with respect to WT -HIVpHXB2 (black bar). Average
values and standard deviation are illustrated. Each data point is the average of four independent experiments. (A) SQV, (B) RTV, (C) IDV, and (D) NFV.
73PROTEOLYTIC ACTIVITY AND DRUG SUSCEPTIBILITY OF HIV-1
coding the L90M substitution was resistant to RTV (five-
fold) and slightly less sensitive to NFV (twofold) than WT
-HIVpHXB2.
Taken together, these results indicated that the pres-
ence of single primary resistance mutations decreased
the HIV-1 protease drug susceptibility, but never reached
a level of resistance as high as we previously described
for phages encoding multiple mutated proteases (Mar-
tinez et al., 2000). In addition, similar to that found when
the proteolytic activities of these mutants were analyzed,
a wide range of different drug susceptibilities was found,
demonstrating that this system can reproducibly distin-
guish small differences in PI susceptibilities.
DISCUSSION
Despite the complex pattern of mutations related to PI
resistance, it has been previously demonstrated that
some of them play a major role in conferring drug resis-
tance. Primary resistance mutations are the first muta-
tions selected in PI-treated patients (Hirsch et al., 2000;
Nijhuis et al., 1999). Primary resistance mutations gen-
erally decrease inhibitor binding to the enzyme and are
considered critical in the development of drug resistance
(Hirsch et al., 2000). Within the HIV-1 protease gene, the
seven amino acid changes D30N, M46L, G48V, I50V,
V82A, I84V, and L90M analyzed in this study correspond
to primary resistance mutations for the inhibitors RTV,
SQV, IDV, NFV, and amprenavir. In a previous article, we
described a simple genetic screen system to evaluate
the activity and phenotype of the HIV-1 protease (Mar-
tinez et al., 2000). Here, we tested if this genetic assay
could be used to characterize HIV-1 protease single
variants. We demonstrate that HIV-1 protease primary
resistance mutations modify the activity and phenotype
of the enzyme. Importantly, different protease single mu-
tants displayed different catalytic efficiencies and differ-
ent PI resistance profiles.
Except for amino acid changes M46L and I84V, the
introduction of one primary resistance mutation in the
protease gene resulted in a significant reduction of the
catalytic efficiency of -HIV-1ps (Fig. 1). All but amino
acid 46 and 90 are located in the substrate-binding cleft
of the enzyme (Boden and Markowitz, 1998). Thus, pri-
mary resistance mutations generally decrease inhibitor
binding to the enzyme, allowing the virus to grow in a
drug-containing medium (Maschera et al., 1996; Schock
et al., 1996). Moreover, these mutations impair the repli-
cation capability of the virus (Mammano et al., 2000;
Nijhuis et al., 1999). For this reason, complex genotypic
patterns are observed in vivo, probably reflecting the
interplay of multiple substitutions to reach equilibrium
between drug resistance and proteolytic activity. Our
analysis confirms that the presence of one primary re-
sistance mutation generally resulted in a worse catalytic
efficiency of the enzyme, but none originated a nonfunc-
tional protein (Fig. 1). Interestingly, we are able to quan-
tify the catalytic defect of these enzymes and to distin-
guish various degrees of proteolytic activity. Accordingly,
specific growth values of phages encoding single mutant
proteases were 1- to 20-fold lower than the WT enzyme,
depending on the modified position. These results dem-
onstrate that the genetic screen system used here was
reproducible and sensitive enough to allow the quantifi-
cation of a wide range of different proteolytic activities.
Overall, our results are in agreement with previous stud-
ies in which protease primary mutations were introduced
on purified proteases (Gulnik et al., 1995; Shao et al.,
1997) or HIV-1 infectious clones. Thus, the low proteolytic
activity observed in this study with the D30N mutant
supports the ex vivo decreased replicative capacity of a
virus clone encoding this single substitution (Martinez-
Picado et al., 1999). Moreover, in the former study the
D30N mutant was also the least fit of the HIV-1 mutants
compared. The single mutation G48V also affected the
growth efficiency of the phage encoding this substitution
(Fig. 1), confirming the loss of infectivity of viruses en-
coding this substitution (Mammano et al., 2000). Analo-
gous to our results, a loss of infectivity has been ob-
served in viruses encoding the single mutation V82A
(Mammano et al., 2000), while virus clones encoding the
single mutations M46L or L90M have been shown to be
as infectious as the WT virus (Mammano et al., 2000;
Martinez-Picado et al., 2000).
Genotypic analysis of HIV-1 variants that escape drug
pressure has allowed for the identification of multiple
amino acid changes consistently related to drug resis-
tance. In fact, we previously demonstrated that phages
encoding proteases obtained from patients failing anti-
retroviral therapy and harboring many resistance muta-
tions were highly resistance to most PIs tested (Martinez
et al., 2000). Now, our results show that primary resis-
tance mutations, despite a decreased proteolytic activity,
increased IC50 values for RTV, SQV, IDV, and NFV (Table
2 and Fig. 2), although none of the seven mutations
analyzed confer the high level of resistance conferred by
multiple mutated HIV-1 proteases. An interesting result of
the present study has been the finding that the phage
encoding the substitution D30N was more susceptible to
RTV (15-fold) than WT -HIVpHXB2 (Fig. 2B). This result
may imply that this mutation may improve posterior ther-
apy with RTV. Importantly, patients failing NFV therapy
who have accumulated the D30N mutation conserved a
good response to RTV and SQV therapy (Markowitz et al.,
1998; Tebas et al., 1999; Zolopa et al., 1999). Furthermore,
hypersusceptibility to ritonavir has been observed in
viruses, obtained from treated patients, with the D30N
mutation (Obry et al., 2002).
The high level of specificity of the genetic system used
here in which modest differences in catalytic efficiency
can be quantified should be useful for the characteriza-
tion of an in vitro generated library of mutated -HIV-1ps.
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Using this system, a rapid selection of novel PI-resistant
mutants system has been recently reported (Sices et al.,
2001). Coupling random sequences with positive genetic
selection will allow the study of functional mutants,
which are unlikely to be readily isolated from HIV-1-
infected patients. Protease mutants may be of interest in
the characterization of the catalytic properties of the
enzyme in the absence or presence of drugs (M. Cabana
and M. A. Martı´nez, unpublished results). The lambda-
based genetic screening assay differs from current ex
vivo methods for detection of phenotypic resistance to
HIV-1 protease inhibitors in that it needs M concentra-
tions of drug (Table 2) to inhibit 50% of phage-replicative
events (IC50), whereas the IC50 values calculated with the
ex vivo assays are in the nM range for the four protease
inhibitors tested (Martinez et al., 2000). However, previ-
ous results obtained either with phages carrying wild-
type or with mutated proteases demonstrated that this
genetic screening assay can be used to monitor HIV-1
protease inhibition at M concentrations of drug (Mar-
tinez et al., 2000). PI resistance is a result of the stepwise
accumulation of amino acids substitutions in the HIV-1
protease as well as in the different cleavage sites of gag
and gag-pol, which are substrates for the viral protease.
Characterization of the enzymatic activity of mutants con-
ferring PI resistance may be clinically relevant since
some PI-resistant HIV-1 replicate less efficiently and can
contribute to the preservation of CD4 cells (Bleiber et
al., 2001; Stoddart et al., 2001). We have validated here a
simple genetic screen system which can be a useful tool
in the analysis of the contribution of individual mutations
on the protease-coding region as well as in the gag and
gag-pol cleavage sites during the complex process of PI
resistance.
MATERIALS AND METHODS
Construction of HIV-1 protease single mutants
HIV-1 protease single mutants D30N, M46L, G48V,
I50V, V82A, I84V, and L90M were constructed by site-
directed mutagenesis using a recombinant PCR protocol
(Rashtchian et al., 1992). A 486-bp fragment (HXB2 posi-
tions 2117 to 2603) was PCR amplified from HXB2-in-
fected cell DNA in two fragments, one 5- and one 3-
PCR product. For the amplification of the 5 fragment the
UDGECOL primer (sense) (Table 1) was used together
with an antisense primer containing the desired muta-
tion. For the amplification of the 3 fragment the UDGE-
COR (antisense) primer (Table 1) was employed together
with a sense primer containing the desired mutation. The
positive-strand (sense) and negative-strand (antisense)
primers used in the mutagenesis procedure are listed in
Table 1. The PCR mixture contained 20 pmol of each
primer, 200 M deoxynucleoside triphosphate, 2.5 mM
MgCl2, PCR buffer [10 mM Tris–HCl (pH 8.3), 50 mM KCl]
and 0.5 U AmpliTaq Gold DNA Polymerase (Applied Bio-
systems) in total reaction volume of 100 l. Cycling
parameters were one cycle of denaturation at 95°C for
10 min and then 35 cycles of denaturation at 95°C for
30 s, annealing at 55°C for 30 s and extension at 72°C
TABLE 1
Synthetic Oligonucleotide Primers Used for Site-Directed Mutagenesis
Primer names Primer sequences (5 to 3)a Position in HXB2 sequence
Forward primers
UDGECOL 5-CUACUACUACUAGGGGAATTCTAAGGCCAGGGAATTTTCTTC-3 2117–2136
UGDECOR 5-CAUCAUCAUCAUGGGGAATTCAAAGGCCATCCATTCCTGGC-3 2603–2587
UDG30NF 5-CUGGAGCUGAUAAUACAGUAUUAGAAGAAATGAGTTTGCC-3 2327–2367
UDG46LF 5-CUAAAUUGAUAGGUGGAAUUGGAGGTTTTATCAAAGTAAG-3 2382–2421
UDG48VF 5-CCUAAAAUGAUAGUGGGAAUAGGUGGAUUTATCAAAGTAAG-3 2381–2421
UDG50VF 5-AUGAUAGGUGGAGUUGGAGGUUUUAUCAAAGTAAGACAGTATG-3 2387–2430
UDG82AF 5-GUAGGACCUACACCUGCCAAUAUAAUAGGUAGAAATCTGTTGAC-3 2480–2523
UDG84VF 5-CCUACUCCAGUCAACGUAAUAGGUAGAAAUCTGTTGACTCAG-3 2486–2527
UDG90MF 5-GUAGAAAUCUGAUGACUCAGAUUGGUTGCACTTTAAAATTTTCCC-3 2507–2548
Reverse primers
UDG30NR 5-AUACUGUAUUAUCAGCUCCAGUATCTAATAGAGCTTCC-3 2348–2311
UDG46LR 5-AUUCCACCUAUCAAUUUAGGUTTCCATCTTCCTGGCAAAC-3 2399–2361
UDG48VR 5-AUCCACCUAUUCCCACUAUCAUUUUAGGUTTCCATCTTCC-3 2408–2369
UDG50VR 5-UAAAACCUCCAACUCCACCUAUCAUUTTTGGTTTCCATCTTCC-3 2411–2369
UDG82AR 5-CCUAUUAUAUUGGCAGGUGUAGGUCCUACUAATACTGTACC-3 2508–2467
UDG84VR 5-UUCUACCUAUUACGUUGACUGGAGUAGGUCCTACTAATACTG-3 2513–2472
UDG90MR 5-CCAAUCUGAGUCAUCAGAUUUCUACCUATTATGTTGACAGG-3 2532–2492
a Bold type indicates the fragment of the primer homologous to HXB2. Italics indicate EcoRI cleavage site. The 5 sequence containing deoxy-UMP
residues is used to clone the PCR product in the CLONEAMPpAMP1 System. Underlined letters indicate changes in nucleotide sequence respect
HXB2 that produce desired mutation. Forward primers were used to amplify the 3 fragment of the protease-coding region. Reverse primers are those
used to amplify the 5 fragment.
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for 30 s. This was followed by a 7-min incubation at 72°C.
5- and 3-PCR products were mixed with pAMP1 vector
DNA (Clone-Amp pAMP System, Gibco-BRL) and di-
gested with uracil DNA glycosilase (Gibco-BRL) for 20
min at 37°C followed by 10 min at 68°C. E. coli XL-1 Blue
electrocompetent cells were then transformed and
screened for white colonies on ampicillin-IPTG-X-GaL
plates. A small-scale plasmid preparation was carried
out to recover bacterial DNA.
Construction of recombinant phages
Plasmid preparations were digested with EcoRI, li-
gated to EcoRI-digested bacteriophage lambda ZapII
(Stratagene), and packaged in vitro. Phage stocks were
prepared from the correct insert orientation. Phage DNA
sequencing confirmed the presence of the desired mu-
tation.
Determination of proteolytic activity and PIs
susceptibility
E. coli JM109 cells containing the plasmid p2X-cI.HIV
were transformed with plasmid pcI.HIV-cro as previously
described (Martinez et al., 2000). The resulting cells were
grown in the presence of 0.2% maltose, harvested by
centrifugation, and suspended to 2.0 OD600 per ml in 10
mM MgSO4. Cells (200 l) were infected with 5  10
7
PFU of phages containing the different HIV-1 proteases
(-HIV-1p). After 15 min at 37°C, the cells were washed
with 1 ml of 10 mM MgSO4, harvested by centrifugation,
and suspended in 1 ml of LB medium containing 12.5 g
tetracycline, 0.2% maltose, 10 mM MgSO4, 0.1 mM IPTG,
and the appropriate drug concentration (see Table 2).
The cell cultures were incubated at 37°C for 3 h and
harvested by centrifugation. An additional cycle of selec-
tive growth was done by suspending the infected cells
with a fresh aliquot (200 l) of JM109 pcI.HIV-cro cells.
After two selective growth cycles the titer of the resulting
phage was determined by coplating the cultures with 200
l E. coli XL-1 Blue cells (OD600  2.0/ml in per in 10 mM
MgSO4) on LB plates using 3 ml top agar containing 12.5
g of tetracycline per ml, 0.2% maltose, 0.1 mM IPTG, and
the indicated drug concentration (see Table 2). After
incubation at 37°C for 6 h, the plaques were counted for
growth scores.
Protease inhibitors
Indinavir (IND), ritonavir, saquinavir, and nelfinavir
were obtained from Merck & Co. (West Point, PA), Abbot
Laboratories (Park Road, IL), Roche Laboratories (Lon-
don, U.K.), and Agouron Pharmaceuticals (San Diego,
CA), respectively.
Statistical analyses
Statistical significance of the difference on selective
growth between phages encoding different HIV-1 pro-
teases was established by a nonparametric statistical
treatment (Mann–Whitney U test) included in the SPSS
version 9.0.1 software package (SPSS Inc.).
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